European Lung Cancer Congress 2024 (ELCC 2024)

In an observational study conducted in Poland, individuals who participated in a low-dose computed tomography (LDCT) lung cancer screening programme had a reduction in all-cause mortality compared with a matched control group extracted from a general Polish cohort.

Following first-line (1L) brigatinib treatment, most patients with ALK-positive (ALK+) non-small-cell lung cancer (NSCLC) received an ALK tyrosine kinase inhibitor (TKI) as second-line (2L) therapy and experienced prolonged clinical benefit, a retrospective chart review of patients enrolled in the phase III ALTA-1L trial has shown.

Treatment with nivolumab plus chemotherapy before surgery followed by nivolumab after surgery yields superior outcomes for patients with resectable nonsmall cell lung cancer (NSCLC) as compared with placebo plus chemotherapy, regardless of the number of completed neoadjuvant cycles, according to an exploratory analysis of the CHECKMATE 77T trial.

Nonsmall cell lung cancer (NSCLC) patients with high PD-L1 expression appear to show a strong preference for receiving atezolizumab subcutaneously rather than intravenously.

Treatment with amivantamab (ami) in combination with chemotherapy (chemo) results in substantially longer time to treatment discontinuation (TTD), time to subsequent therapy (TTST), and progression-free survival (PFS) after first subsequent therapy (PFS2) in patients with EGFR-mutant advanced nonsmall cell lung cancer (NSCLC) following progression on osimertinib, as shown in a postprogression analysis.